Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 9/20 | 0.47 |
| ▸ | HTR1D | P28221 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4724534 | 0.94 | HTR1B (0.44) | HTR1BHTR1DCNR1CNR2SLC6A4 | |
| SCHEMBL4722941 | 0.88 | IFNAR1 (0.40) | HTR1BHTR1D | |
| SCHEMBL4721972 | 0.81 | BRAF (0.41) | L3MBTL1SLC6A4 | |
| SCHEMBL4724774 | 0.80 | CYP1A2 (0.45) | HTR1BHTR1DCYP2C9CYP1A2CYP2C19 | |
| SCHEMBL2251308 | 0.76 | CYP1A2 (0.50) | HTR1BHTR1DGAATDP1L3MBTL1 | |
| SCHEMBL1004658 | 0.75 | HTR1B (0.73) | HTR1BHTR1DCNR1CNR2SLC6A4 | |
| SCHEMBL251001 | 0.75 | CNR1 (0.57) | HTR1BHTR1DGAATDP1L3MBTL1 | |
| SCHEMBL18065342 | 0.74 | IFNAR1 (0.46) | TDP1CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL4723742 | 0.72 | SLC6A9 (0.36) | HTR1BGAAL3MBTL1SLC6A4CYP2C9 | |
| SCHEMBL2254327 | 0.72 | HTR1B (0.46) | HTR1BHTR1DGAATDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC. | 2008-07-24 | — | — | US | disclosed |
| EP-1874780-A1 | 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006100591-A1 | 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | TBXA2R, P2RY4, PF4 | HTR1B 111/4885HTR1D 94/4885GAA 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.